Research programme: AL-amyloid fibrillogenesis inhibitors - Neurochem
Alternative Names: AL-amyloid fibrillogenesis inhibitors research programme - NeurochemLatest Information Update: 02 May 2008
At a glance
- Originator Neurochem
- Developer BELLUS Health
- Class
- Mechanism of Action Amyloid fibril protein AL inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Amyloidosis
Most Recent Events
- 02 May 2008 Discontinued - Preclinical for Amyloidosis in Canada (PO)
- 07 Jul 2006 No development reported - Preclinical for Amyloidosis in Canada (PO)
- 20 Jul 2000 Preclinical development for Amyloidosis in Canada (PO)